DiNAQOR
DiNAQOR is a Swiss privately-held life science company builder developing gene therapies and a closed-loop loco-regional perfusion delivery platform for monogenic cardiac and renal diseases, serving pharmaceutical and biotech partners through a portfolio of specialized subsidiaries.
- Company typePrivate
- Founded2019
- HeadquartersPfäffikon, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What DiNAQOR does
DiNAQOR AG is a privately held Swiss life science company builder founded in 2019 and headquartered in Pfäffikon, Switzerland, with additional R&D operations in Schlieren (Bio-Technopark Zürich), German operations inherited from the EHT Technologies GmbH acquisition, and a US medical device subsidiary in Laguna Hills, California. The company develops gene therapy and precision delivery platforms targeting monogenic cardiomyopathies and renal genetic diseases, built on three proprietary technology pillars: Engineered Heart Tissue (EHT) technology based on human-induced pluripotent stem cell cardiomyocytes for preclinical disease modeling; a closed-loop Loco-Regional Perfusion (LRP) catheter-based delivery system that achieved up to 69,000-fold higher local payload concentration and 75-fold increase in target-organ transduction efficiency in preclinical models; and an AAV vector platform with organ-specific constructs. Its therapeutic pipeline includes DiNA-001 through DiNA-006 (covering HCM, ARVC, and DCM) and DINAK-001 through DINAK-004 (ADPKD and Glomerular Diseases), with DiNA-001 partnered to BioMarin.
The company operates a portfolio of four subsidiaries: DiNAMIQS (AAV viral vector CDMO, 95% owned by Siegfried since May 2023, with a cGMP facility inaugurated September 2025 at up to 500L scale), DiNABIOS (human cell and tissue CDMO), DiNATEQ AG (drug delivery MedTech for the LRP platform, spun out December 2025), and DAiNA (N=1 precision oncology). DiNAQOR generates revenue through licensing and milestone payments (BioMarin agreement covering DiNA-001 with upfront plus development, regulatory, and commercial milestones and tiered royalties), manufacturing services (DiNAMIQS/Siegfried, Lonza for DiNA-001 production), and platform technology licensing to pharmaceutical and biotech partners. The company targets pharmaceutical and biotechnology enterprises seeking gene therapy delivery, manufacturing, and partnership solutions for cardiac and renal genetic disease programs.
DiNAQOR firmographics
Firmographics- Name
- DiNAQOR
- Legal name
- DINAQOR AG
- Website
- https://dinaqor.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- DiNAQOR is a Swiss privately-held life science company builder developing gene therapies and a closed-loop loco-regional perfusion delivery platform for monogenic cardiac and renal diseases, serving pharmaceutical and biotech partners through a portfolio of specialized subsidiaries.
- Ownership category
- akta.pro rank
DiNAQOR industry classification
Industry- Product category
- Gene Therapy & Biotechnology Platforms
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where DiNAQOR is headquartered
LocationHeadquarters
- HQ city
- Pfäffikon
- HQ country
- Switzerland
- HQ region
- Europe
Offices4 records
Markets served
DiNAQOR business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain
Revenue model
- Licensing and Milestone Payments: DiNAQOR receives upfront payments, development, regulatory and commercial milestones, and tiered royalties on worldwide sales from licensing agreements with pharmaceutical partners such as BioMarin for programs like DiNA-001 for MYBPC3 hypertrophic cardiomyopathy.
- Manufacturing Services: Through DiNAMIQS (now majority-owned by Siegfried), DiNAQOR accesses GMP manufacturing capabilities for viral vectors, providing end-to-end manufacturing from vector design to aseptic drug product filling.
- Technology Platform Licensing: DiNAQOR licenses its LRP delivery platform technology to pharmaceutical and biotechnology partners for use with their therapeutic assets, offering differentiated delivery solutions that enhance therapeutic index.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
DiNAQOR product offering
Product offeringCore offering
DiNAQOR is a Swiss-headquartered life science company builder that creates and scales focused biotechnology companies around differentiated gene therapy technology platforms. It combines proprietary Engineered Heart Tissue (EHT) technology, a closed-loop Loco-Regional Perfusion (LRP) delivery system, and AAV vector engineering to advance monogenic cardiomyopathy and renal disease programs. Revenue is generated through licensing deals, milestone payments, royalties, and CDMO services delivered via its portfolio subsidiaries (DiNAMIQS, DiNABIOS, DiNATEQ AG, DAiNA).
Product overview
DiNAQOR is a Swiss-headquartered life science company builder operating a multi-platform portfolio of distinct subsidiaries and technology offerings. The core comprises DiNATEQ AG (precision drug delivery MedTech advancing the closed-loop Loco-Regional Perfusion platform), DiNAMIQS (AAV viral vector CDMO spun out and now majority-owned by Siegfried), DiNABIOS (AI-driven human cell and tissue CDMO), and DAiNA (N=1 precision oncology). Underpinning the portfolio are two proprietary technology platforms: Engineered Heart Tissue (EHT) based on hiPSC cardiomyocytes, and the Loco-Regional Perfusion (LRP) system for organ-isolated delivery. The therapeutic pipeline includes multiple gene therapy programs spanning monogenic cardiomyopathies (DINA-001 through DINA-006 covering HCM, ARVC, DCM) and monogenic renal diseases (DINAK-001 through DINAK-004 for ADPKD and Glomerular Diseases), with programs partnered with BioMarin, Lonza, and UCL.
Differentiator
Problem solved
Functional benefit
Brands
- DiNAMIQS: CDMO for advanced medicine providing GMP-compatible capabilities and scalable viral vector manufacturing services.
- DiNABIOS
- DiNATEQ AG
- DAiNA
Products and services
- DiNAMIQS (AAV Viral Vector CDMO)
- DiNABIOS (Human Tissue & Stem Cell CDMO)
- DiNATEQ AG (Loco-Regional Perfusion Delivery Platform)
- DAiNA (N=1 Precision Oncology Platform)
- Engineered Heart Tissue (EHT) Technology Platform
- LRP Delivery Platform Licensing
Quantifiable outcome
- Up to 69,000-fold higher local payload concentration compared to conventional intravenous administration
- +3 more outcomes
Companies that use DiNAQOR
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
DiNAQOR technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
DiNAQOR partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Charité – Universitätsmedizin BerlincoreAcademic partnership for development of closed-loop loco-regional perfusion (LRP) platform. Professor Maximilian Y. Emmert led the landmark study published in JACC: Basic to Translational Science demonstrating the LRP technology.
- ETH ZurichcoreAcademic partner in landmark LRP delivery platform research published in JACC: Basic to Translational Science.
- Siegfried AG (DiNAMIQS)coreDiNAMIQS, established in 2022 and spun out from DiNAQOR as independent entity in 2023, has been acquired with 95% equity by Siegfried. New cGMP viral vector manufacturing facility inaugurated, enabling end-to-end manufacturing from vector design to drug product filling.
- Siegfried Holding AGcoreDiNAQOR sold 95% stake in DiNAMIQS to Siegfried, who is building a high-end GMP compliant facility for viral vector manufacturing at 500L scale. DiNAQOR remains a minority equity holder and close partner. Investment was mid double-digit millions Swiss Francs.
- Children's Medical Research Institute (CMRI)minorResearch collaboration to develop novel bioengineered AAV capsids for cardiac-specific gene therapy delivery. CMRI provides AAV capsid library; DiNAQOR provides EHT technology for screening. DiNAQOR has option to exclusive license co-developed capsids for cardiovascular and kidney diseases.
- EHT Technologies GmbHcoreDiNAQOR acquired EHT Technologies GmbH, a Germany-based engineered heart tissue (EHT) technology platform company founded in 2015 based on research at University Medical Center Hamburg-Eppendorf.
- BioMarin PharmaceuticalcorePreclinical collaboration and license agreement to develop gene therapies for rare genetic cardiomyopathies. DiNAQOR received undisclosed upfront payment and is eligible for development, regulatory, and commercial milestones plus tiered royalties. Covers DiNA-001 for MYBPC3 HCM with option to extend to other programs.
- UCL (University College London)coreResearch collaboration and exclusive license agreement with UCL Business Ltd to develop gene therapies for monogenic cardiomyopathies. DiNAQOR obtains worldwide rights to therapies developed. Royalties to UCL upon commercialization. Based on research of Professor Thomas Voit at UCL GOSH Institute of Child Health.
- LonzacoreStrategic collaboration for DiNAQOR's AAV gene therapy production system. Lonza provides preclinical, clinical and commercial production support for DiNA-001 at Houston, TX facility. Focus on MYBPC3 cardiomyopathies.
Scale indicators6 records
Recent moves11 records
Expansion highlights6 records
DiNAQOR competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
DiNAQOR social profiles
Digital presenceDiNAQOR financial estimates
Financial estimateRevenue estimate
Valuation estimate
DiNAQOR leadership team
Management profileNumber of profiles
Profiles8 records
DiNAQOR subsidiaries and ownership
Company hierarchySubsidiaries4 records
DiNAQOR funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DiNAQOR M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DiNAQOR
What does DiNAQOR do?
DiNAQOR is a Swiss-headquartered life science company builder that creates and scales focused biotechnology companies around differentiated gene therapy technology platforms. It combines proprietary Engineered Heart Tissue (EHT) technology, a closed-loop Loco-Regional Perfusion (LRP) delivery system, and AAV vector engineering to advance monogenic cardiomyopathy and renal disease programs. Revenue is generated through licensing deals, milestone payments, royalties, and CDMO services delivered via its portfolio subsidiaries (DiNAMIQS, DiNABIOS, DiNATEQ AG, DAiNA).
Is DiNAQOR a public or private company?
DiNAQOR is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DiNAQOR founded?
DiNAQOR was founded in 2019. It employs 1 to 10 people.
Where is DiNAQOR based?
DiNAQOR is headquartered in Pfäffikon, Switzerland, in the Europe region.
How does DiNAQOR make money?
Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are manufacturing Services and technology Platform Licensing.
Does DiNAQOR have an API?
No public API is recorded for DiNAQOR.
What industry is DiNAQOR in?
DiNAQOR's product category is Gene Therapy & Biotechnology Platforms. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 8731.